These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 29948020)

  • 1. Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications.
    Huang C; Liu S; Tong X; Fan H
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):171-183. PubMed ID: 29948020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
    Ashida A; Sakaizawa K; Uhara H; Okuyama R
    Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
    Iijima Y; Hirotsu Y; Amemiya K; Ooka Y; Mochizuki H; Oyama T; Nakagomi T; Uchida Y; Kobayashi Y; Tsutsui T; Kakizaki Y; Goto T; Miyashita Y; Omata M
    Eur J Cancer; 2017 Nov; 86():349-357. PubMed ID: 29078173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA testing in advanced non-small cell lung cancer.
    Moding EJ; Diehn M; Wakelee HA
    Lung Cancer; 2018 May; 119():42-47. PubMed ID: 29656751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions.
    Liu Z; Han Y; Dang Q; Xu H; Zhang Y; Duo M; Lv J; Li H; Kong Y; Han X
    Int Immunopharmacol; 2022 Oct; 111():109173. PubMed ID: 35998502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Circulating Tumor DNA in Renal Cell Carcinoma.
    Bergerot PG; Hahn AW; Bergerot CD; Jones J; Pal SK
    Curr Treat Options Oncol; 2018 Feb; 19(2):10. PubMed ID: 29464405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
    Goldberg SB; Narayan A; Kole AJ; Decker RH; Teysir J; Carriero NJ; Lee A; Nemati R; Nath SK; Mane SM; Deng Y; Sukumar N; Zelterman D; Boffa DJ; Politi K; Gettinger SN; Wilson LD; Herbst RS; Patel AA
    Clin Cancer Res; 2018 Apr; 24(8):1872-1880. PubMed ID: 29330207
    [No Abstract]   [Full Text] [Related]  

  • 9. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
    Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
    Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic profiling of cancer with circulating tumor DNA analysis.
    Lu L; Bi J; Bao L
    J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasensitive Detection of Circulating Tumor DNA of Lung Cancer via an Enzymatically Amplified SERS-Based Frequency Shift Assay.
    Zhang J; Dong Y; Zhu W; Xie D; Zhao Y; Yang D; Li M
    ACS Appl Mater Interfaces; 2019 May; 11(20):18145-18152. PubMed ID: 31050289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-Cell Lung Cancer: Is Liquid Biopsy a New Tool Able to Predict the Efficacy of Immunotherapy?
    Fasano R; Serratì S; Rafaschieri T; Longo V; Di Fonte R; Porcelli L; Azzariti A
    Biomolecules; 2024 Mar; 14(4):. PubMed ID: 38672414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
    Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
    Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular Vesicles in Cancer Detection: Hopes and Hypes.
    Hu T; Wolfram J; Srivastava S
    Trends Cancer; 2021 Feb; 7(2):122-133. PubMed ID: 33008796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy.
    Cabel L; Proudhon C; Romano E; Girard N; Lantz O; Stern MH; Pierga JY; Bidard FC
    Nat Rev Clin Oncol; 2018 Oct; 15(10):639-650. PubMed ID: 30050094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab.
    Raja R; Kuziora M; Brohawn PZ; Higgs BW; Gupta A; Dennis PA; Ranade K
    Clin Cancer Res; 2018 Dec; 24(24):6212-6222. PubMed ID: 30093454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients.
    Koldby KM; Mortensen MB; Detlefsen S; Pfeiffer P; Thomassen M; Kruse TA
    J Gastroenterol; 2019 Feb; 54(2):108-121. PubMed ID: 30242476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer.
    Romero A; Serna-Blasco R; Calvo V; Provencio M
    Curr Treat Options Oncol; 2021 Aug; 22(10):86. PubMed ID: 34424428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunities of circulating tumor DNA in lung cancer.
    Wu TH; Hsiue EH; Yang JC
    Cancer Treat Rev; 2019 Aug; 78():31-41. PubMed ID: 31326635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid biopsies.
    Lianidou E; Pantel K
    Genes Chromosomes Cancer; 2019 Apr; 58(4):219-232. PubMed ID: 30382599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.